Coronary mortality in China: fence, ambulance, or hospital treatments?

Circ Cardiovasc Qual Outcomes. 2014 Jan;7(1):8-10. doi: 10.1161/CIRCOUTCOMES.113.000761. Epub 2014 Jan 14.

Authors

George A Mensah¹, Uchechukwu K A Sampson

Affiliation

¹ National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD.

PMID: 24425711
DOI: 10.1161/CIRCOUTCOMES.113.000761

No abstract available

Keywords: China; Editorials; cardiovascular diseases; coronary disease; decision modeling; prevention and control.

Publication types

Editorial
Comment

MeSH terms

Adrenergic beta-Antagonists / therapeutic use*
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Aspirin / therapeutic use*
Coronary Disease / mortality*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Myocardial Infarction / drug therapy*
Myocardial Infarction / economics*

Substances

Adrenergic beta-Antagonists
Angiotensin-Converting Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Aspirin